Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Sodium Tetradecyl Sulfate→

Sodium Tetradecyl Sulfate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
139-88-8
Molecular formula
C14H29NaO4S
Molecular weight
316.43 g/mol
Drug class
Anionic surfactant sclerosantdetergent-type venous sclerotherapy agent
Mechanism of action
Disrupts endothelial-cell membranes in the treated vein, causing endothelial injury, thrombosis and subsequent fibrotic occlusion of the vessel. Sodium is a counter-ion and does not create a different sclerosant target.
Indications / reported uses
  • Sclerotherapy of suitable varicose veins and venous malformations in appropriately selected patients; strength, foam/solution technique and target vessel are product- and jurisdiction-specific

Sources: US DailyMed — Sodium tetradecyl sulfate injection · NICE — Varicose veins: diagnosis and management

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Sodium Tetradecyl Sulfate Environmental Risk Assessment (ERA) (the Sodium Tetradecyl Sulfate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.